Earnings Releases·Nov 9, 2026, 7:17 AM ET

Roivant — Q2 2026 Earnings Summary

Consolidated product revenue reached $31.0 million in Q2 2026, driven by LISRAYA's first 5 weeks of sales, while total net revenues rose to $35.1 million from $1.6 million in the prior year period; net loss narrowed to $153.0 million from $166.0 million, though net loss attributable to Roivant increased to $191.6 million from $113.5 million.
The company repurchased 2.1 million common shares for approximately $72.5 million during the quarter, while cash, cash equivalents, and marketable securities totaled $4.2 billion as of September 30, 2026.
Genevant received an initial $950 million payment from Moderna's patent infringement settlement, with an additional $1.3 billion contingent on a favorable resolution of Moderna's Section 1498 appeal.
Clinical and regulatory milestones include the initiation of the Phase 3 PHrontier study for mosliciguat, a planned sNDA filing for brepocitinib in NIU in H1 2027, and upcoming FDA meetings for IMVT-1402 in D2T RA later in 2026.
Development of IMVT-1402 in Sjögren's disease will not advance beyond Phase 2 due to the evolving landscape, while the drug met primary endpoints in D2T RA and mosliciguat demonstrated positive Phase 2 data in PH-ILD.